JP2009519962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519962A5 JP2009519962A5 JP2008545889A JP2008545889A JP2009519962A5 JP 2009519962 A5 JP2009519962 A5 JP 2009519962A5 JP 2008545889 A JP2008545889 A JP 2008545889A JP 2008545889 A JP2008545889 A JP 2008545889A JP 2009519962 A5 JP2009519962 A5 JP 2009519962A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- mecamylamine
- eye
- individual
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000009472 formulation Methods 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 48
- 229960002525 mecamylamine Drugs 0.000 claims 23
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 claims 19
- 208000024891 symptom Diseases 0.000 claims 9
- 208000002780 macular degeneration Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 5
- 239000002738 chelating agent Substances 0.000 claims 5
- 239000003755 preservative agent Substances 0.000 claims 5
- 230000008728 vascular permeability Effects 0.000 claims 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 4
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 239000006172 buffering agent Substances 0.000 claims 3
- 210000003161 choroid Anatomy 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical group O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 208000038018 age-related macular disease Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940124274 edetate disodium Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 238000000554 physical therapy Methods 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75180805P | 2005-12-19 | 2005-12-19 | |
| US83860506P | 2006-08-17 | 2006-08-17 | |
| US85958206P | 2006-11-17 | 2006-11-17 | |
| PCT/US2006/048487 WO2007075720A2 (en) | 2005-12-19 | 2006-12-18 | Topical mecamylamine formulations for ocular administration and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519962A JP2009519962A (ja) | 2009-05-21 |
| JP2009519962A5 true JP2009519962A5 (enExample) | 2010-02-12 |
Family
ID=38218545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545889A Withdrawn JP2009519962A (ja) | 2005-12-19 | 2006-12-18 | 眼投与用局所メカミルアミン製剤およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070167526A1 (enExample) |
| EP (1) | EP1978926A2 (enExample) |
| JP (1) | JP2009519962A (enExample) |
| KR (1) | KR20080081175A (enExample) |
| AU (1) | AU2006331790A1 (enExample) |
| BR (1) | BRPI0620080A2 (enExample) |
| CA (1) | CA2633655A1 (enExample) |
| IL (1) | IL192206A0 (enExample) |
| WO (1) | WO2007075720A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110098312A1 (en) * | 2008-05-12 | 2011-04-28 | Targacept ,Inc | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| WO2012118833A2 (en) * | 2011-02-28 | 2012-09-07 | The Trustees Of Columbia University In The City Of New York | Identificationof c3 complement molecule at the site of injury to blood vessels in the retina of oxygen exposed animals |
| US20140018402A1 (en) * | 2011-03-30 | 2014-01-16 | Catholic University Industry Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating macular degeneration |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA3002384C (en) * | 2015-10-25 | 2021-02-16 | Iview Therapeutics, Inc. | Pharmaceutical formulations that form gel in situ |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| JP6490124B2 (ja) * | 2017-03-07 | 2019-03-27 | ファナック株式会社 | レーザ加工装置および機械学習装置 |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2831027A (en) * | 1955-06-06 | 1958-04-15 | Merck & Co Inc | Isocamphane compounds and processes for preparing the same |
| KR830002802B1 (ko) * | 1978-12-04 | 1983-12-16 | 제임스 에프 · 너우톤 | 박테리아 발효에 의한 다당류 s-60의 제조방법 |
| US4326053A (en) * | 1978-12-04 | 1982-04-20 | Merck & Co., Inc. | Polysaccharide S-60 and bacterial fermentation process for its preparation |
| US5686448A (en) * | 1983-01-10 | 1997-11-11 | Baltech, Inc. | Treatment of virus infections with ganglionic blocking agents |
| US4503038A (en) * | 1983-02-25 | 1985-03-05 | The Regents Of The University Of California | Extracellular nonmitogenic angiogenesis factor and method of isolation thereof from wound fluid |
| FR2588189B1 (fr) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US4966890A (en) * | 1986-04-04 | 1990-10-30 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
| US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
| US4888354A (en) * | 1987-12-21 | 1989-12-19 | Theratech, Inc. | Skin penetration enhancement using free base and acid addition salt combinations of active agents |
| IE62662B1 (en) * | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
| US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
| AU4467396A (en) * | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
| FR2754712B1 (fr) * | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | Compositions ophtalmiques |
| US5932545A (en) * | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
| US6034079A (en) * | 1997-08-11 | 2000-03-07 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| US6159458A (en) * | 1997-11-04 | 2000-12-12 | Insite Vision | Sustained release ophthalmic compositions containing water soluble medicaments |
| US6174524B1 (en) * | 1999-03-26 | 2001-01-16 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
| DK1083889T3 (da) * | 1998-06-01 | 2004-04-13 | Ortho Mcneil Pharm Inc | Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme |
| US6121289A (en) * | 1998-10-09 | 2000-09-19 | Theramax, Inc. | Method for enhanced brain delivery of nicotinic antagonist |
| US7973068B2 (en) * | 1998-10-20 | 2011-07-05 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| DK1634498T3 (da) * | 1998-12-16 | 2008-12-15 | Univ South Florida | Exo-S-mecamylamine formulation |
| US6734215B2 (en) * | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
| BR0012787A (pt) * | 1999-07-28 | 2002-07-30 | Univ Leland Stanford Junior | Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora |
| JP2003505507A (ja) * | 1999-07-28 | 2003-02-12 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 治療的血管新生および脈管形成におけるニコチン |
| US6337076B1 (en) * | 1999-11-17 | 2002-01-08 | Sg Licensing Corporation | Method and composition for the treatment of scars |
| WO2001052832A1 (en) * | 2000-01-18 | 2001-07-26 | Valley Forge Pharmaceuticals, Inc. | Ocular growth and nicotinic antagonists |
| US20030096831A1 (en) * | 2000-01-18 | 2003-05-22 | Stone Richard A. | Ocular growth and nicotinic antagonists |
| US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| JP5000835B2 (ja) * | 2000-08-25 | 2012-08-15 | 千寿製薬株式会社 | 水性懸濁液剤 |
| US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| US7045534B2 (en) * | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| US20030158112A1 (en) * | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
| JP3683235B2 (ja) * | 2002-07-03 | 2005-08-17 | 松下電器産業株式会社 | 密閉型圧縮機 |
| JP4750421B2 (ja) * | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | α７受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US7149574B2 (en) * | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
| US8512717B2 (en) * | 2003-08-07 | 2013-08-20 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050075702A1 (en) * | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
-
2006
- 2006-12-18 EP EP06845848A patent/EP1978926A2/en not_active Withdrawn
- 2006-12-18 BR BRPI0620080-0A patent/BRPI0620080A2/pt not_active Application Discontinuation
- 2006-12-18 CA CA002633655A patent/CA2633655A1/en not_active Abandoned
- 2006-12-18 KR KR1020087017606A patent/KR20080081175A/ko not_active Withdrawn
- 2006-12-18 AU AU2006331790A patent/AU2006331790A1/en not_active Abandoned
- 2006-12-18 WO PCT/US2006/048487 patent/WO2007075720A2/en not_active Ceased
- 2006-12-18 US US11/641,192 patent/US20070167526A1/en not_active Abandoned
- 2006-12-18 JP JP2008545889A patent/JP2009519962A/ja not_active Withdrawn
-
2008
- 2008-06-16 IL IL192206A patent/IL192206A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2399045T3 (es) | Combinación de brimonidina y timolol para uso oftálmico tópico | |
| ES2316867T3 (es) | Uso de rimexolona en el tratamiento del ojo seco. | |
| ES2405779T3 (es) | Gotas oftálmicas con difluprednato para tratamiento del edema macular | |
| US20110021974A1 (en) | Retinitis pigmentosa treatment and prophalaxis | |
| JP2015526467A5 (enExample) | ||
| WO2001041806A1 (en) | Ophthalmic compositions | |
| ES2709180T3 (es) | Soluciones de brimonidina y timolol sin conservantes | |
| JP6214726B2 (ja) | スクアラミンの眼用製剤 | |
| RU2012131251A (ru) | Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз | |
| JP2009519962A5 (enExample) | ||
| ES2295161T3 (es) | Solucion oftalmica. | |
| JP2011144111A (ja) | 軸性近視の予防または治療剤 | |
| Day et al. | Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension | |
| ES2324200T3 (es) | Medicamentos oftalmologicos retino-protectores, que comprenden ramipril o ramiprilato. | |
| CA2453442A1 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
| ES2583127T3 (es) | Aplicación transdérmica de prostaglandina E1 para el tratamiento de la isquemia ocular | |
| Khan et al. | Beyond the local effect: an examination of cardiovascular and other systemic complications of ophthalmologic drugs | |
| Kiernan et al. | Topical drug delivery for posterior segment disease | |
| CN104703606B (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用 | |
| JP2012513393A (ja) | 眼の後区に、有効濃度の活性剤を送達するための、眼の局部に用いる溶液の組成物 | |
| US20060004089A1 (en) | Use of an l-ascorbic acid salt to prepare a pharmaceutical composition for ophthalmic topical use capable of improving the level of l-ascorbic acid in the eye | |
| US20040259844A1 (en) | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage | |
| CA2442296A1 (en) | Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients | |
| Arcinue et al. | Corticosteroids in uveitis | |
| JPH10203979A (ja) | チアプロフェン酸を含有する抗眼炎症剤 |